REDUCE-IT Trial Presents Updated Findings
on the REDUCE-IT trial were presented by CMHC faculty member Deepak Bhatt, MD at an American College of Cardiology event in late March. The originally released report examined the impact of icosapent ethyl 2 g among patients with, and at risk of, high triglycerides and found a 25% reduction in first cardiovascular events. The updated findings examined the impact of the drug on total cardiovascular events-- incorporating a broader window of patient data. In the total event analysis, researchers found a 30% reduction in CVD events.
AHA/ACC Release Updated Guidelines On Primary Prevention of CVD
The American College of Cardiology and the American Heart Association recently published an updated version
of the Primary Prevention of Cardiovascular Disease guideline. A notable change within the guideline is the recommendation against the broad use of aspirin in primary prevention. Additionally, the document highlights a healthy lifestyle as "the most important part of prevention throughout the entire lifespan,” but also notes that “only 10% to 20% of our health is actually determined by the healthcare that we receive, and 70% to 80% is impacted by social determinants of health. Underserved and low-income populations have a higher risk of heart disease and life expectancy can vary by more than 20 years in people living only 5 miles apart.”
Newly Released Findings on Detecting AF with an Apple Watch
led by Stanford University and presented at an American College of Cardiology event observed the ability of the Apple Watch in identifying atrial fibrillation (AF) by monitoring irregular heart rhythms in over 400,000 users. The study found that the watch was able to identify an irregular pulse in 0.5% of the research population. While investigators were primarily encouraged by the study’s findings, they emphasized the nascent and inconclusive nature of the research. While discussing the study’s findings, Mattew Martinez, MD, chair of the ACC Sports & Excercise Council echoed the observation of many cardiologists observing the growing trend towards wearable medical technology: “This technology is coming whether we like it or not. Like many other instances, the technology here is ahead of the science but we need to try and keep up with it as best we can."
Nova Nordisk Files for FDA Approval for Oral Semaglitude
Novo Nordisk recently announced
the submission of two New Drug Applications (NDA) to the US Food and Drug Administration (FDA) for oral semaglutide. If approved, the drug will be the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist in a pill. The first application submitted seeks approval
as “an adjunct to diet and exercise to improve blood sugar in adults with type 2 diabetes,” while the second seeks approval for “an indication to reduce the risk of major adverse cardiovascular events (MACE) such as heart attack, stroke, or death in adults with type 2 diabetes and established CVD.” Concurrently, Novo Nordisk filed a supplemental NDA (sNDA) for once-weekly semaglutide injection 0.5 mg or 1 mg.
ADA Releases Critical Update on Standards for Diabetes Care
The American Diabetes Association issued critical updates to the the 2019 Standards of Medical Care in Diabetes
. The document has been revised to include newly published research that provides optimal treatment recommendation for patients with CVD and diabetes and patients with chronic kidney disease and diabetes. Among others, the updates included research from the REDUCE-IT and DECLARE-TIMI 58 trials. In a publicly released statement, ADA’s Chief Scientific, Medical, and Mission Officer William T. Cefalu, MD noted:"New research can lead to improved patient outcomes and quality of life, and the American Diabetes Association is proud to continue to provide the most current evidence-based guidelines for people living with diabetes.”